Discontinued — last reported Q2 '16

Other

Change in Other Liabilities

Vertex Pharmaceuticals Change in Other Liabilities remained flat by 0.0% to $37.13M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 274.1%, from $9.93M to $37.13M. Over 2 years (FY 2023 to FY 2025), Change in Other Liabilities shows a downward trend with a -15.7% CAGR.

Analysis

StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityVolatile
First reportedQ1 2015
Last reportedQ2 2016

How to read this metric

An increase represents a source of cash flow, while a decrease represents a use of cash to settle obligations.

Detailed definition

Reflects the net movement in miscellaneous liabilities not classified under primary debt or accounts payable categories...

Peer comparison

Standard line item in cash flow statements across all industries.

Metric ID: is_anet_change_in_other_liabilities

Historical Data

3 years
 FY'23FY'24FY'25
Value$208.90M$39.70M$148.50M
YoY Change—-81.0%+274.1%
Range$39.70M – $208.90M
CAGR-15.7%
Avg YoY Growth+96.5%
Median YoY Growth+96.5%

Frequently Asked Questions

What is Vertex Pharmaceuticals's change in other liabilities?
Vertex Pharmaceuticals (VRTX) reported change in other liabilities of $37.13M in Q4 2025.
How has Vertex Pharmaceuticals's change in other liabilities changed year-over-year?
Vertex Pharmaceuticals's change in other liabilities increased by 274.1% year-over-year, from $9.93M to $37.13M.
What is the long-term trend for Vertex Pharmaceuticals's change in other liabilities?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's change in other liabilities has grown at a -15.7% compound annual growth rate (CAGR), from $208.90M to $148.50M.
What does change in other liabilities mean?
The net change in miscellaneous debt and accrual obligations over the period.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.